Keyword

BGB324

Description: BGB324, also called bemcentinib, is a small-molecule inhibitor of the AXL receptor tyrosine kinase studied in cancer treatment.
Wikidata ID: wiki/Q27236818
OpenAlex ID: keywords/bgb324
2018 · Hirokazu Sadahiro, Kyung-Don Kang, et al. · Cancer Research · 157
2018 · Milena S. Espindola, David M. Habiel, et al. · American Journal of Respiratory and Critical Care Medicine · 110
2020 · Michaël H. Meel, Mark C. de Gooijer, et al. · Clinical Cancer Research · 73
2014 · Emmy D.G. Fleuren, Melissa H.S. Hillebrandt-Roeffen, et al. · Oncotarget · 56
2022 · Marta Nyakas, Karianne Giller Fleten, et al. · Scientific Reports · 54
2019 · Jeanne M. Quinn, Molly M. Greenwade, et al. · Molecular Cancer Therapeutics · 54
2019 · Mai Tanaka, Dietmar W. Siemann · Oncotarget · 51
2020 · Karine Flem-Karlsen, Marta Nyakas, et al. · PLoS ONE · 47
2016 · Anne Von Mässenhausen, Johannes Brägelmann, et al. · International Journal of Molecular Sciences · 47
2016 · Stuart Dowall, Kevin Bewley, et al. · Viruses · 47
2017 · Isabel Ben-Batalla, Robert Erdmann, et al. · Clinical Cancer Research · 46
2017 · Marguerite L. Palisoul, Jeanne M. Quinn, et al. · Molecular Cancer Therapeutics · 34
2015 · Melanie Janning, Isabel Ben-Batalla, et al. · Expert Review of Hematology · 28
2019 · Pei-Wen Yang, Yu-Cheng Liu, et al. · Frontiers in Oncology · 24
2021 · Mai Tanaka, Samantha S. Dykes, et al. · Clinical & Experimental Metastasis · 23
2024 · Zihang Liu, Li Chen, et al. · European Journal of Medicinal Chemistry · 22
Works count: 146
Citation count: 1,865
Year
Topic
Type